Literature DB >> 7688561

Activation interferes with the APO-1 pathway in mature human T cells.

C Klas1, K M Debatin, R R Jonker, P H Krammer.   

Abstract

One of the mechanisms to terminate a specific immune response may involve elimination of antigen activated T cells by programmed cell death, apoptosis. Apoptosis in activated T cells may be induced via the TCR-CD3 complex or/and cell surface molecules like the APO-1 (Fas) antigen, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily. To investigate apoptosis in activated T cells we studied expression of APO-1 and sensitivity to APO-1 mediated apoptosis in human peripheral T lymphocytes. APO-1 is not expressed on cord blood and the majority of resting T cells, but on activated T cells. One day activated T cells in culture showed activation induced resistance to apoptosis (ARA). However, after prolonged in vitro culture, 6 day activated T cells acquired sensitivity to activation induced sensitivity to apoptosis (ASA). Restimulation of the ASA+ activated T cells by triggering TCR-CD3 or CD2 induced proliferation and apoptosis in a fraction of the cells. In the surviving fraction of ASA+ activated T cells, however, this treatment reinduced a transient ARA+ phenotype. Thus, activation of resting mature T cells or restimulation of activated T cells may induce a transient resistance to apoptotic signals. Activation signals may interfere with the APO-1 pathway and may prevent elimination of activated T cells in the periphery (peripheral selection).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688561     DOI: 10.1093/intimm/5.6.625

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  82 in total

1.  T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.

Authors:  M Karas; T Z Zaks; J L Liu; D LeRoith
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

Review 2.  Death and destruction of activated T lymphocytes.

Authors:  I N Crispe
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

3.  Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation.

Authors:  M Di Renzo; Z Zhou; I George; K Becker; C Cunningham-Rundles
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

4.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L).

Authors:  D C Huang; M Hahne; M Schroeter; K Frei; A Fontana; A Villunger; K Newton; J Tschopp; A Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly.

Authors:  T H Holmström; I Schmitz; T S Söderström; M Poukkula; V L Johnson; S C Chow; P H Krammer; J E Eriksson
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

6.  Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes.

Authors:  Patrick T Walsh; Loraine M Smith; Rosemary O'Connor
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

7.  Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.

Authors:  I Herr; D Wilhelm; T Böhler; P Angel; K M Debatin
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

8.  Lack of activation induced cell death in human T blasts despite CD95L up-regulation: protection from apoptosis by MEK signalling.

Authors:  L S Walker; J D McLeod; G Boulougouris; Y I Patel; C N Ellwood; N D Hall; D M Sansom
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

Review 9.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

10.  Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway.

Authors:  D Ashany; X Song; E Lacy; J Nikolic-Zugic; S M Friedman; K B Elkon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.